Dr. Eric Fischer, Ph.D. is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School (HMS) and Dana-Farber Cancer Institute (DFCI). Dr. Fischer obtained his PhD in 2013 from the University of Basel, Switzerland. After postdoctoral studies at the Friedrich Miescher Institute for Biomedical Research, Eric joined HMS/DFCI as an Assistant Professor in 2015 and was promoted through the ranks to full Professor in 2023. Additionally, he currently serves as the Director of the Chemical Biology Program, Director of the Center for Protein Degradation, and co-director of the Center for Therapeutics Discovery, all DFCI. He is also an Associate Member of the Broad Institute of Harvard and MIT.  

Dr. Fischer is a world leading expert in the area of targeted protein degradation using chemical strategies to induce selective degradation of therapeutically relevant proteins. His laboratory focuses on molecular design of such chemical matter and mechanistic understanding of how these molecules exert their cellular effects. In this context, understanding protein complexes that play critical roles in ubiquitin signaling, especially the molecular workings of E3 ubiquitin ligases, enzymes that catalyze the ultimate step of ubiquitin transfer to the substarte protein, are also of paramount importance. Over the last decade, Dr. Fischer has made seminal contributions to our mechanistic understanding of E3 ubiquitin ligases, small molecule induced protein degradation, and translational application of targeted protein degradation as a new pharmacological modality. Dr. Fischers is recognozied as a leading chemical biologists in targeted protein degradation and translational chemical biology, as illustrated by his role as a founder and advisor of several biotechnology companies.